Apolipoprotein E epsilon4 allele frequency in elderly depressed patients with and without cerebrovascular disease.
Late-onset depression (LOD) could be a very early manifestation of Alzheimer's disease (AD), although contradictory results have been reported. Cerebrovascular disease (CVD) may favor the development of LOD, and that the particular forms of vascular depression should be individualized. The Apolipoprotein E (ApoE) epsilon4 allele was shown to be a risk factor for AD. Its role in LOD is controversial, while it is still unknown in vascular depression. Our objective was to clarify the relationship between ApoE epsilon4 allele and LOD in patients with and without CVD. We examined the ApoE phenotypes in a sample of 311 subjects: 50 with vascular LOD, 24 with LOD without CVD, 115 with AD and 122 normal controls (NC). The study of the ApoE epsilon4 allele frequency showed significant differences between: AD group and the vascular LOD and NC groups; LOD group without CVD compared with NC group (p<0.05 to 0.001). The frequency of the epsilon4 allele in the LOD group without CVD did not differ significantly from the AD group, similarly the frequency of the epsilon4 allele in the vascular LOD group was not different from that in NC. The study suggests an association between the ApoE epsilon4 allele and the LOD without CVD. These patients could be at risk of developing AD by an epsilon4-dependent pathway. In contrast, the results show no association between the presence of ApoE epsilon4 allele and vascular depression and provide further evidence in support of the concept that ApoE epsilon4 allele is not associated with clinical CVD.
Traykov
Latchezar
L
Hôpital Broca, Paris, France. traykov_i@yahoo.fr
Bayle
Anne Catherine
AC
Latour
Florence
F
Lenoir
Hermine
H
Seux
Marie-Laure
ML
Hanon
Olivier
O
Péquignot
Renaud
R
Bert
Pierre
P
Moulin
Florence
F
Cantegreil
Inge
I
Wenisch
Emilie
E
Batouche
Fériel
F
Mehrabian
Shima
S
Rotrou
Jocelyne de
Jd
Rigaud
Anne-Sophie
AS
D017668:Age of Onset; D000368:Aged; D000369:Aged, 80 and over; D000375:Aging / Q000235:genetics* / Q000523:psychology; D000544:Alzheimer Disease / Q000150:complications / Q000235:genetics*; D053327:Apolipoprotein E4 / Q000235:genetics*; D002561:Cerebrovascular Disorders / Q000150:complications / Q000235:genetics* / Q000523:psychology; D004252:DNA Mutational Analysis; D003866:Depressive Disorder / Q000150:complications / Q000235:genetics*; D042241:Early Diagnosis; D005260:Female; D005787:Gene Frequency / Q000235:genetics; D005819:Genetic Markers; D020022:Genetic Predisposition to Disease / Q000235:genetics*; D005820:Genetic Testing; D005838:Genotype; D006801:Humans; D008297:Male; D010641:Phenotype; D011110:Polymorphism, Genetic / Q000235:genetics; D011237:Predictive Value of Tests; D011379:Prognosis; D012307:Risk Factors
D053327:Apolipoprotein E4; D005819:Genetic Markers